Literature DB >> 24093029

Addressing the authorization of orphan drugs will not fix reimbursement problems: The elephant is still in the room.

Mark Embrett1.   

Abstract

Entities:  

Year:  2013        PMID： 24093029      PMCID： PMC3785191          DOI： 10.1177/1715163513499127

Source DB:  PubMed          Journal:  Can Pharm J (Ott)        ISSN： 1715-1635


× No keyword cloud information.
  2 in total

1.  The National Pharmaceuticals Strategy: Rest in peace, revive or renew?

Authors:  Neil J MacKinnon; Ivan Ip
Journal:  CMAJ       Date:  2009-02-03       Impact factor: 8.262

2.  Qualitative evaluation of the Canadian Fabry Disease Initiative.

Authors:  Mark Embrett; Neil J Mackinnon
Journal:  Can Pharm J (Ott)       Date:  2012-05
  2 in total
  1 in total

Review 1.  Translating rare-disease therapies into improved care for patients and families: what are the right outcomes, designs, and engagement approaches in health-systems research?

Authors:  Beth K Potter; Sara D Khangura; Kylie Tingley; Pranesh Chakraborty; Julian Little
Journal:  Genet Med       Date:  2015-04-09       Impact factor: 8.822
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.